EP0673385A4 - Mammalian gap-43 compositions and methods of use. - Google Patents

Mammalian gap-43 compositions and methods of use.

Info

Publication number
EP0673385A4
EP0673385A4 EP93920048A EP93920048A EP0673385A4 EP 0673385 A4 EP0673385 A4 EP 0673385A4 EP 93920048 A EP93920048 A EP 93920048A EP 93920048 A EP93920048 A EP 93920048A EP 0673385 A4 EP0673385 A4 EP 0673385A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
mammalian gap
mammalian
gap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93920048A
Other languages
German (de)
French (fr)
Other versions
EP0673385A1 (en
Inventor
Mark C Fishman
Howard Federoff
Mauricio Zuber
Stephen Strittmatter
Dario Valenzuela
Shi-Chung Ng
Edward Grabczyk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP0673385A1 publication Critical patent/EP0673385A1/en
Publication of EP0673385A4 publication Critical patent/EP0673385A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
EP93920048A 1992-08-13 1993-08-13 Mammalian gap-43 compositions and methods of use. Withdrawn EP0673385A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92892092A 1992-08-13 1992-08-13
US928920 1992-08-13
PCT/US1993/007643 WO1994004562A1 (en) 1992-08-13 1993-08-13 Mammalian gap-43 compositions and methods of use

Publications (2)

Publication Number Publication Date
EP0673385A1 EP0673385A1 (en) 1995-09-27
EP0673385A4 true EP0673385A4 (en) 1995-11-29

Family

ID=25457006

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93920048A Withdrawn EP0673385A4 (en) 1992-08-13 1993-08-13 Mammalian gap-43 compositions and methods of use.

Country Status (2)

Country Link
EP (1) EP0673385A4 (en)
WO (1) WO1994004562A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1133556B1 (en) * 1998-11-24 2006-02-08 Pioneer Hi-Bred International, Inc. Root-preferred promoters and their use
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
CA2425610A1 (en) * 2000-10-13 2002-04-18 University Of Lausanne Intracellular delivery of biological effectors by novel transporter peptide sequences
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
CA2903275A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006948A1 (en) * 1988-12-22 1990-06-28 Fishman Mark C Mammalian gap-43 compositions and methods of use
WO1991013078A1 (en) * 1990-03-02 1991-09-05 Amoco Corporation Biosynthesis of carotenoids in genetically engineered hosts
WO1992018138A1 (en) * 1991-04-10 1992-10-29 The General Hospital Corporation Mammalian gap-43 compositions and methods of use
WO1993006851A1 (en) * 1991-10-11 1993-04-15 The General Hospital Corporation Mammalian gap-43 compositions and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006948A1 (en) * 1988-12-22 1990-06-28 Fishman Mark C Mammalian gap-43 compositions and methods of use
WO1991013078A1 (en) * 1990-03-02 1991-09-05 Amoco Corporation Biosynthesis of carotenoids in genetically engineered hosts
WO1992018138A1 (en) * 1991-04-10 1992-10-29 The General Hospital Corporation Mammalian gap-43 compositions and methods of use
WO1993006851A1 (en) * 1991-10-11 1993-04-15 The General Hospital Corporation Mammalian gap-43 compositions and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO9404562A1 *
Y. SUDO ET AL.: "Palmitoylation alters protein activity: blockade of G0 stimulation by GAP-43", EMBO JOURNAL, vol. 11, no. 6, EYNSHAM, OXFORD GB, pages 2095 - 2102 *

Also Published As

Publication number Publication date
EP0673385A1 (en) 1995-09-27
WO1994004562A1 (en) 1994-03-03

Similar Documents

Publication Publication Date Title
ZA931613B (en) Conditioning shampoo composition and method of preparing and using the same
ZA949668B (en) Optionally crosslinkable coatings compositions and methods of use
GB2294465A8 (en) Perfluoroelastomeric compositions and methods
HU9401580D0 (en) Method for the preparation and popification of alphia - interferon
EP0556447A3 (en) Surfactant composition and method of making the same
ZA9410078B (en) Methods of inhibiting atrophy of the skin and vagina
EP0728019A4 (en) Labelled diagnostic compositions and methods of their use
EP0707480A4 (en) Antineoplastic compositions and methods of use
EP0673385A4 (en) Mammalian gap-43 compositions and methods of use.
HU9600241D0 (en) Mutable composition and methods of use thereof
AU1753892A (en) Mammalian gap-43 compositions and methods of use
HU9402361D0 (en) New makrolides and use of them
AU8427091A (en) Gamma-carboxylase and methods of use
EP0585168A3 (en) Composition and methods for the generation of bone
GB2294637B (en) Therapeutic compositions and methods of use
EP0583687A3 (en) Method for the preparation of substituted methoxyphenols and microorganisms therefore
GB9222985D0 (en) Use of the tarchonanthus camphoratus
ZA932553B (en) New use of B-carbolines
EP0737204A4 (en) Cs-1 peptidomimetics, compositions and methods of using the same
GB9200519D0 (en) Composition of matter
GB9016027D0 (en) Composition and use
AU629651B2 (en) 5-phenyl-2-furan ketones and use as antiepileptic agents
AU2867092A (en) Mammalian gap-43 compositions and methods of use
EP0407543A4 (en) Mammalian gap-43 compositions and methods of use
GB9216776D0 (en) Composition and use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950313

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: C07K 5/10

A4 Supplementary search report drawn up and despatched

Effective date: 19951016

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GRABCZYK, EDWARD SEC. ON GENOMIC STRUC/FUNCTION

Inventor name: NG, SHI-CHUNG

Inventor name: VALENZUELA, DARIO

Inventor name: STRITTMATTER, STEPHEN

Inventor name: ZUBER, MAURICIO

Inventor name: FEDEROFF, HOWARD

Inventor name: FISHMAN, MARK, C.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GRABCZYK, EDWARD SEC. ON GENOMIC STRUC/FUNCTION

Inventor name: NG, SHI-CHUNG

Inventor name: VALENZUELA, DARIO

Inventor name: STRITTMATTER, STEPHEN

Inventor name: ZUBER, MAURICIO

Inventor name: FEDEROFF, HOWARD

Inventor name: FISHMAN, MARK, C.

17Q First examination report despatched

Effective date: 19971030

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980311